Mercer Global Advisors
PDLI

Mercer Global Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Mercer Global Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-79,289
Closed -$224K – 1227
2020
Q1 		$224K Sell
79,289
-3,747
-5% -$12.1K ﹤0.01% 912
2019
Q4 		$269K Buy
83,036
+16,378
+25% +$47.5K 0.01% 960
2019
Q3 		$143K Buy
66,658
+4,692
+8% +$12.5K ﹤0.01% 1056
2019
Q2 		$195K Buy
61,966
+127
+0.2% +$412 0.01% 1060
2019
Q1 		$230K Buy
+61,839
New +$209K 0.01% 936

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Mercer Global Advisors's PDLI Position: Q2 2020 in Review

Mercer Global Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q2 2020, closing a stake of 79,289 shares — an estimated $224K sold.

Mercer Global Advisors first reported a position in PDLI in Q1 2019 and held it in 5 quarters. The position peaked at $269K in Q4 2019. 136 funds tracked by Wall St. Rank hold PDLI as of Q2 2020.

  • Mercer Global Advisors reported no remaining PDL BioPharma, Inc. position as of Q2 2020 after selling out during the quarter.
  • Mercer Global Advisors sold 79,289 PDL BioPharma, Inc. shares in Q2 2020, an estimated $224K.
  • Mercer Global Advisors first reported a position in PDL BioPharma, Inc. in Q1 2019 and held it in 5 quarters.
  • Mercer Global Advisors's PDL BioPharma, Inc. position peaked at $269K in Q4 2019.
  • 136 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2020.

Based on Mercer Global Advisors's 13F filing for Q2 2020, filed 10 Aug 2020.